0 109

Cited 1 times in

Effects of renin-angiotensin-aldosterone-system inhibitors on coronary atherosclerotic plaques: The PARADIGM registry

Authors
 Curtis Williams  ;  Donghee Han  ;  Hidenobu Takagi  ;  Christopher B Fordyce  ;  Stephanie Sellers  ;  Philipp Blanke  ;  Fay Y Lin  ;  Leslee J Shaw  ;  Sang-Eun Lee  ;  Daniele Andreini  ;  Mouaz H Al-Mallah  ;  Matthew J Budoff  ;  Filippo Cademartiri  ;  Kavitha Chinnaiyan  ;  Jung Hyun Choi  ;  Edoardo Conte  ;  Hugo Marques  ;  Pedro de Araújo Gonçalves  ;  Ilan Gottlieb  ;  Martin Hadamitzky  ;  Erica Maffei  ;  Gianluca Pontone  ;  Sanghoon Shin  ;  Yong-Jin Kim  ;  Byoung Kwon Lee  ;  Eun Ju Chun  ;  Ji Min Sung  ;  Renu Virmani  ;  Habib Samady  ;  Peter H Stone  ;  Daniel S Berman  ;  Jagat Narula  ;  Jeroen J Bax  ;  Jonathon A Leipsic  ;  Hyuk-Jae Chang 
Citation
 ATHEROSCLEROSIS, Vol.383 : 117301, 2023-10 
Journal Title
ATHEROSCLEROSIS
ISSN
 0021-9150 
Issue Date
2023-10
MeSH
Aldosterone ; Angiotensins ; Computed Tomography Angiography ; Coronary Angiography ; Coronary Artery Disease* / complications ; Coronary Artery Disease* / diagnostic imaging ; Coronary Artery Disease* / drug therapy ; Coronary Vessels ; Disease Progression ; Humans ; Plaque, Atherosclerotic* / complications ; Predictive Value of Tests ; Prospective Studies ; Registries ; Renin ; Renin-Angiotensin System
Keywords
ACE inhibitor ; Coronary CT angiography ; Plaque morphology ; Plaque progression ; RAAS inhibitor ; Stable coronary artery disease
Abstract
Background and aims: Inhibition of Renin-Angiotensin-Aldosterone-System (RAAS) has been hypothesized to improve endothelial function and reduce plaque inflammation, however, their impact on the progression of coronary atherosclerosis is unclear. We aim to study the effects of RAAS inhibitor on plaque progression and composition assessed by serial coronary CT angiography (CCTA).

Methods: We performed a prospective, multinational study consisting of a registry of patients without history of CAD, who underwent serial CCTAs. Patients using RAAS inhibitors were propensity matched to RAAS inhibitor naïve patients based on clinical and CCTA characteristics at baseline. Atherosclerotic plaques in CCTAs were quantitatively analyzed for percent atheroma volume (PAV) according to plaque composition. Interactions between RAAS inhibitor use and baseline PAV on plaque progression were assessed in the unmatched cohort using a multivariate linear regression model.

Results: Of 1248 patients from the registry, 299 RAAS inhibitor taking patients were matched to 299 RAAS inhibitor naïve patients. Over a mean interval of 3.9 years, there was no significant difference in annual progression of total PAV between RAAS inhibitor naïve vs taking patients (0.75 vs 0.79%/year, p = 0.66). With interaction testing in the unmatched cohort, however, RAAS inhibitor use was significantly associated with lower non-calcified plaque progression (Beta coefficient -0.100, adjusted p = 0.038) with higher levels of baseline PAV.

Conclusions: The use of RAAS inhibitors over a period of nearly 4 years did not significantly impact on total atherosclerotic plaque progression or various plaque components. However, interaction testing to assess the differential effect of RAAS inhibition based on baseline PAV suggested a significant decrease in progression of non-calcified plaque in patients with a higher burden of baseline atherosclerosis, which should be considered hypothesis generating.
Full Text
https://www.sciencedirect.com/science/article/pii/S002191502305222X
DOI
10.1016/j.atherosclerosis.2023.117301
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Sang-Eun(이상은) ORCID logo https://orcid.org/0000-0001-6645-4038
Chang, Hyuk-Jae(장혁재) ORCID logo https://orcid.org/0000-0002-6139-7545
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/197215
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links